查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951925

消化器官系統藥物市場分析及預測（至2035年）：類型、產品、應用、最終用戶、技術、劑型、成分、製程及模式

Gastrointestinal Drugs Market Analysis and Forecast to 2035: Type, Product, Application, End User, Technology, Form, Component, Process, Mode
出版日期: | 出版商: Global Insight Services | 英文 362 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計到2034年，消化器官系統藥物市場規模將從2024年的612億美元成長至1,014億美元，複合年成長率約為5.3%。消化器官系統藥物市場涵蓋用於治療消化器官系統疾病的藥物，例如酸相關疾病、便秘和發炎性腸道疾病。推動市場成長的因素包括胃腸道疾病盛行率的上升、人口老化以及人們對腸道健康的日益關注。藥物遞送系統和生物製藥的創新正在提高治療效果和患者依從性，而新興市場則提供了成長機會。該市場競爭激烈，重點在於研發和策略合作，以滿足尚未滿足的市場需求。

受胃腸道疾病發病率上升和藥物製劑技術進步的推動，消化器官系統藥物市場正經歷強勁成長。酸中和劑，尤其是質子幫浦阻斷劑，因其在治療酸相關疾病方面的有效性而表現突出。止吐藥，特別是5-羥色胺受體拮抗劑，因其在控制噁心和嘔吐方面的有效性而成為表現第二好的細分市場。生物製藥因其能夠為發炎性腸道疾病等慢性疾病提供標靶治療日益受到重視。非處方藥市場需求不斷成長，反映出消費者對更便利治療方案的偏好。處方藥仍然佔據主導地位，創新治療方法正在改善患者的治療效果。新型藥物遞送系統（例如緩釋製劑）的開發正在提高治療效果和患者依從性。策略聯盟和研發投資正在加速先進消化器官系統藥物的上市，進一步提升市場潛力。對個人化醫療的關注有望改變治療模式，並帶來巨大的成長機會。

市場區隔
類型 制酸劑、瀉藥、止瀉藥、抗潰瘍藥、止吐藥、生物製藥製劑、質子幫浦阻斷劑、H2受體阻斷劑
產品 錠劑、膠囊、粉末、液體、注射、凝膠劑、栓劑、乳膏劑
適應症 大腸激躁症、胃食道逆流、消化性潰瘍、克隆氏症、潰瘍性大腸炎、乳糜瀉、憩室炎、功能性消化不良
最終用戶 醫院、診所、居家醫療機構、專科護理中心、研究機構、診斷中心、學術機構、製藥公司
科技 生物技術、合成、奈米技術、重組DNA、高通量篩檢
形式 固體、液態、固體
成分 活性藥物成分、添加劑、防腐劑、色素、粘合劑、潤滑劑、包衣劑
流程 配方、生產、包裝、品管、分銷
形式 處方藥和非處方藥

消化器官系統藥物市場產品組合豐富多樣，現有企業透過策略定價和創新產品推出維持顯著的市場佔有率。新參與企業取得了顯著進展，尤其是在新型製劑和標靶治療，滿足了尚未被滿足的醫療需求。競爭格局瞬息萬變，各公司正利用先進的藥物遞送系統來提高療效和病患依從性。定價策略競爭激烈，反映了可及性和盈利之間的平衡。在新興市場，由於醫療保健意識的提高和對有效胃腸道治療的需求，市場滲透率正在不斷成長。競爭基準分析顯示，少數幾家主要企業佔據主導地位，而規模較小的企業也透過提供利基產品來擴大市場佔有率。監管影響顯著，嚴格的核准流程決定企業的市場准入和擴張。食品藥物管理局) 和歐洲藥品管理局 (EMA) 在製定影響藥物生命週期管理的標準方面發揮關鍵作用。市場分析表明，在生物製藥技術的進步推動下，個人化醫療正在成為一種趨勢。數據分析和真實世界數據 (RWE) 擴大被用於完善市場策略和最佳化藥物開發過程，從而獲得競爭優勢。

主要趨勢和促進因素：

受胃腸道疾病發病率上升和全球人口老化趨勢的推動，消化器官系統藥物市場正經歷強勁成長。關鍵趨勢包括新型生物製劑和生物相似藥的研發，這些藥物提供標靶治療，並具有更高的療效和安全性。個人化醫療的進步也在重塑市場格局，使治療方法能夠根據患者的個別需求量身定做。肥胖和糖尿病等文明病的增加推動了對消化器官系統藥物的需求。緩釋製劑等藥物傳遞系統的進步提高了病患的遵從性和治療效果。此外，數位健康技術的整合正在革新病患管理，提供即時監測和個人化治療方案。新興市場擁有完善的醫療基礎設施，並不斷擴大先進療法的覆蓋範圍，蘊藏著許多機會。投資研發以滿足未被滿足的醫療需求的公司，將更有利於掌握這些成長前景。對經濟高效且易於獲得的治療方案的關注，也為市場擴張開闢了新的途徑。在創新和不斷發展的患者照護模式的驅動下，消化器官系統藥物市場有望取得重大進展。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 制酸劑
    • 瀉藥
    • 止瀉
    • 抗潰瘍藥物
    • 止吐藥
    • 生物製藥
    • 質子幫浦阻斷劑
    • H2受體拮抗劑
  • 市場規模及預測：依產品分類
    • 藥片
    • 膠囊
    • 粉末
    • 液體
    • 注射
    • 凝膠
    • 栓劑
    • 奶油
  • 市場規模及預測：依應用領域分類
    • 大腸激躁症
    • 胃食道逆流症
    • 消化性潰瘍病
    • 克隆氏症
    • 潰瘍性大腸炎
    • 乳糜瀉
    • 憩室炎
    • 功能性消化不良
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診所
    • 居家醫療環境
    • 專業醫療中心
    • 研究所
    • 診斷中心
    • 學術機構
    • 製藥公司
  • 市場規模及預測：依技術分類
    • 生物技術
    • 合成
    • 奈米科技
    • 重組DNA
    • 高通量篩檢
  • 市場規模及預測：依類型
    • 固態的
    • 液體
    • 半固態
  • 市場規模及預測：依組件分類
    • 原料藥
    • 添加劑
    • 防腐劑
    • 著色劑
    • 吸附劑
    • 潤滑劑
    • 塗層劑
  • 市場規模及預測：依製程分類
    • 配方
    • 製造業
    • 包裝
    • 品管
    • 分配
  • 市場規模及預測：按模式
    • 處方藥
    • 非處方藥

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Ironwood Pharmaceuticals
  • Salix Pharmaceuticals
  • Almirall
  • Ferring Pharmaceuticals
  • Ardelyx
  • Red Hill Biopharma
  • Phathom Pharmaceuticals
  • Antibe Therapeutics
  • Innovate Biopharmaceuticals
  • Progenity
  • Synthetic Biologics
  • Genfit
  • Galectin Therapeutics
  • 9 Meters Biopharma
  • Trulance
  • Iterum Therapeutics
  • Assembly Biosciences
  • Adare Pharmaceuticals
  • Theravance Biopharma
  • Sterna Biologicals

第9章：關於我們

簡介目錄
Product Code: GIS31474

Gastrointestinal Drugs Market is anticipated to expand from $61.2 billion in 2024 to $101.4 billion by 2034, growing at a CAGR of approximately 5.3%. The Gastrointestinal Drugs Market encompasses pharmaceuticals designed to treat digestive system disorders, including acid-related diseases, constipation, and inflammatory bowel conditions. This market is driven by rising prevalence of gastrointestinal diseases, aging populations, and increasing awareness of gut health. Innovations in drug delivery systems and biologics are enhancing treatment efficacy and patient compliance, while emerging markets offer growth opportunities. The market is characterized by a competitive landscape with a focus on R&D and strategic collaborations to address unmet medical needs.

The Gastrointestinal Drugs Market is experiencing robust growth, propelled by rising incidences of gastrointestinal disorders and advancements in drug formulations. The acid neutralizers segment, particularly proton pump inhibitors, leads in performance due to their efficacy in treating acid-related conditions. Antiemetics, especially serotonin receptor antagonists, emerge as the second highest-performing sub-segment, driven by their effectiveness in managing nausea and vomiting. Biologics are gaining prominence, offering targeted therapies for chronic conditions like inflammatory bowel disease. The over-the-counter drugs segment is witnessing increased demand, reflecting consumer preference for accessible treatment options. Prescription drugs continue to dominate, with innovative therapies enhancing patient outcomes. The development of novel drug delivery systems, such as extended-release formulations, is enhancing therapeutic efficacy and patient compliance. Strategic collaborations and research investments are accelerating the introduction of advanced gastrointestinal drugs, further boosting market potential. The focus on personalized medicine is anticipated to transform treatment paradigms, offering significant growth opportunities.

Market Segmentation
TypeAntacids, Laxatives, Antidiarrheal, Antiulcerants, Antiemetics, Biologics, Proton Pump Inhibitors, H2 Receptor Antagonists
ProductTablets, Capsules, Powders, Liquids, Injectables, Gels, Suppositories, Creams
ApplicationIrritable Bowel Syndrome, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Crohn's Disease, Ulcerative Colitis, Celiac Disease, Diverticulitis, Functional Dyspepsia
End UserHospitals, Clinics, Homecare Settings, Specialty Centers, Research Institutes, Diagnostic Centers, Academic Institutions, Pharmaceutical Companies
TechnologyBiotechnology, Synthetic, Nanotechnology, Recombinant DNA, High-throughput Screening
FormSolid, Liquid, Semi-solid
ComponentActive Pharmaceutical Ingredients, Excipients, Preservatives, Colorants, Binders, Lubricants, Coatings
ProcessFormulation, Manufacturing, Packaging, Quality Control, Distribution
ModePrescription, Over-the-Counter

The Gastrointestinal Drugs Market is characterized by a diverse range of offerings, with established players maintaining significant market share through strategic pricing and innovative product launches. New entrants are making notable strides, particularly with novel formulations and targeted therapies that address unmet medical needs. The competitive landscape is dynamic, with companies leveraging advanced drug delivery systems to enhance efficacy and patient compliance. Pricing strategies remain competitive, reflecting the balance between accessibility and profitability. Emerging markets are witnessing increased penetration, driven by rising healthcare awareness and demand for effective gastrointestinal treatments. Competition benchmarking reveals a landscape dominated by a few key players, yet smaller firms are gaining traction through niche offerings. Regulatory influences are profound, with stringent approval processes shaping market entry and expansion. The FDA and EMA are pivotal in setting standards that affect drug lifecycle management. Market analysis indicates a trend toward personalized medicine, with biopharmaceutical advancements leading the charge. Data analytics and real-world evidence are increasingly utilized to refine market strategies and optimize drug development pathways, enhancing competitive positioning.

Geographical Overview:

The Gastrointestinal Drugs Market is witnessing varied growth across regions, each presenting unique opportunities. North America maintains a dominant position due to a high prevalence of gastrointestinal disorders and significant healthcare expenditure. The region's advanced healthcare infrastructure supports the swift adoption of novel therapies. Europe follows closely, driven by an aging population and increased awareness of gastrointestinal health. In Asia Pacific, the market is expanding rapidly. This growth is fueled by rising healthcare investments and increasing incidences of gastrointestinal diseases. Emerging economies like India and China are pivotal, with their large patient pools and improving healthcare access. Latin America is gradually becoming a significant player, with Brazil and Mexico leading the charge due to growing healthcare initiatives. The Middle East & Africa are also emerging as promising markets. Increased healthcare spending and a growing focus on improving healthcare infrastructure are key drivers. These regions are recognizing the importance of addressing gastrointestinal health to enhance overall population well-being.

Global tariffs and geopolitical dynamics are profoundly influencing the Gastrointestinal Drugs Market, especially in Japan, South Korea, China, and Taiwan. These nations are recalibrating strategies amid US-China trade tensions, with Japan and South Korea enhancing R&D investments to mitigate dependency on imports. China is advancing its pharmaceutical capabilities to counteract trade barriers, while Taiwan leverages its robust biotech sector despite geopolitical vulnerabilities. The parent market is witnessing steady growth driven by rising gastrointestinal disorders and an aging population. By 2035, the market is expected to evolve with increased regional collaboration and innovation in drug formulations. Middle East conflicts exacerbate global supply chain vulnerabilities and elevate energy prices, indirectly impacting production costs and market dynamics in the pharmaceutical sector.

Key Trends and Drivers:

The gastrointestinal drugs market is experiencing robust growth, fueled by rising incidences of gastrointestinal disorders and an aging global population. Key trends include the development of novel biologics and biosimilars, which offer targeted therapies with improved efficacy and safety profiles. The advent of personalized medicine is also shaping the market, with treatments increasingly tailored to individual patient needs. The increasing prevalence of lifestyle-related conditions such as obesity and diabetes is driving demand for gastrointestinal drugs. Advances in drug delivery systems, such as extended-release formulations, are enhancing patient compliance and treatment outcomes. Furthermore, the integration of digital health technologies is revolutionizing patient management, providing real-time monitoring and personalized treatment plans. Opportunities abound in emerging markets where healthcare infrastructure is improving, and access to advanced therapies is expanding. Companies investing in research and development to address unmet medical needs are well-positioned to capitalize on these growth prospects. The focus on cost-effective and accessible treatment options is also opening new avenues for market expansion. The gastrointestinal drugs market is poised for significant advancements, driven by innovation and evolving patient care paradigms.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Application
  • 2.4 Key Market Highlights by End User
  • 2.5 Key Market Highlights by Technology
  • 2.6 Key Market Highlights by Form
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Antacids
    • 4.1.2 Laxatives
    • 4.1.3 Antidiarrheal
    • 4.1.4 Antiulcerants
    • 4.1.5 Antiemetics
    • 4.1.6 Biologics
    • 4.1.7 Proton Pump Inhibitors
    • 4.1.8 H2 Receptor Antagonists
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Tablets
    • 4.2.2 Capsules
    • 4.2.3 Powders
    • 4.2.4 Liquids
    • 4.2.5 Injectables
    • 4.2.6 Gels
    • 4.2.7 Suppositories
    • 4.2.8 Creams
  • 4.3 Market Size & Forecast by Application (2020-2035)
    • 4.3.1 Irritable Bowel Syndrome
    • 4.3.2 Gastroesophageal Reflux Disease
    • 4.3.3 Peptic Ulcer Disease
    • 4.3.4 Crohn's Disease
    • 4.3.5 Ulcerative Colitis
    • 4.3.6 Celiac Disease
    • 4.3.7 Diverticulitis
    • 4.3.8 Functional Dyspepsia
  • 4.4 Market Size & Forecast by End User (2020-2035)
    • 4.4.1 Hospitals
    • 4.4.2 Clinics
    • 4.4.3 Homecare Settings
    • 4.4.4 Specialty Centers
    • 4.4.5 Research Institutes
    • 4.4.6 Diagnostic Centers
    • 4.4.7 Academic Institutions
    • 4.4.8 Pharmaceutical Companies
  • 4.5 Market Size & Forecast by Technology (2020-2035)
    • 4.5.1 Biotechnology
    • 4.5.2 Synthetic
    • 4.5.3 Nanotechnology
    • 4.5.4 Recombinant DNA
    • 4.5.5 High-throughput Screening
  • 4.6 Market Size & Forecast by Form (2020-2035)
    • 4.6.1 Solid
    • 4.6.2 Liquid
    • 4.6.3 Semi-solid
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Active Pharmaceutical Ingredients
    • 4.7.2 Excipients
    • 4.7.3 Preservatives
    • 4.7.4 Colorants
    • 4.7.5 Binders
    • 4.7.6 Lubricants
    • 4.7.7 Coatings
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Formulation
    • 4.8.2 Manufacturing
    • 4.8.3 Packaging
    • 4.8.4 Quality Control
    • 4.8.5 Distribution
  • 4.9 Market Size & Forecast by Mode (2020-2035)
    • 4.9.1 Prescription
    • 4.9.2 Over-the-Counter

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Application
      • 5.2.1.4 End User
      • 5.2.1.5 Technology
      • 5.2.1.6 Form
      • 5.2.1.7 Component
      • 5.2.1.8 Process
      • 5.2.1.9 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Application
      • 5.2.2.4 End User
      • 5.2.2.5 Technology
      • 5.2.2.6 Form
      • 5.2.2.7 Component
      • 5.2.2.8 Process
      • 5.2.2.9 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Application
      • 5.2.3.4 End User
      • 5.2.3.5 Technology
      • 5.2.3.6 Form
      • 5.2.3.7 Component
      • 5.2.3.8 Process
      • 5.2.3.9 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Application
      • 5.3.1.4 End User
      • 5.3.1.5 Technology
      • 5.3.1.6 Form
      • 5.3.1.7 Component
      • 5.3.1.8 Process
      • 5.3.1.9 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Application
      • 5.3.2.4 End User
      • 5.3.2.5 Technology
      • 5.3.2.6 Form
      • 5.3.2.7 Component
      • 5.3.2.8 Process
      • 5.3.2.9 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Application
      • 5.3.3.4 End User
      • 5.3.3.5 Technology
      • 5.3.3.6 Form
      • 5.3.3.7 Component
      • 5.3.3.8 Process
      • 5.3.3.9 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Application
      • 5.4.1.4 End User
      • 5.4.1.5 Technology
      • 5.4.1.6 Form
      • 5.4.1.7 Component
      • 5.4.1.8 Process
      • 5.4.1.9 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Application
      • 5.4.2.4 End User
      • 5.4.2.5 Technology
      • 5.4.2.6 Form
      • 5.4.2.7 Component
      • 5.4.2.8 Process
      • 5.4.2.9 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Application
      • 5.4.3.4 End User
      • 5.4.3.5 Technology
      • 5.4.3.6 Form
      • 5.4.3.7 Component
      • 5.4.3.8 Process
      • 5.4.3.9 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Application
      • 5.4.4.4 End User
      • 5.4.4.5 Technology
      • 5.4.4.6 Form
      • 5.4.4.7 Component
      • 5.4.4.8 Process
      • 5.4.4.9 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Application
      • 5.4.5.4 End User
      • 5.4.5.5 Technology
      • 5.4.5.6 Form
      • 5.4.5.7 Component
      • 5.4.5.8 Process
      • 5.4.5.9 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Application
      • 5.4.6.4 End User
      • 5.4.6.5 Technology
      • 5.4.6.6 Form
      • 5.4.6.7 Component
      • 5.4.6.8 Process
      • 5.4.6.9 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Application
      • 5.4.7.4 End User
      • 5.4.7.5 Technology
      • 5.4.7.6 Form
      • 5.4.7.7 Component
      • 5.4.7.8 Process
      • 5.4.7.9 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Application
      • 5.5.1.4 End User
      • 5.5.1.5 Technology
      • 5.5.1.6 Form
      • 5.5.1.7 Component
      • 5.5.1.8 Process
      • 5.5.1.9 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Application
      • 5.5.2.4 End User
      • 5.5.2.5 Technology
      • 5.5.2.6 Form
      • 5.5.2.7 Component
      • 5.5.2.8 Process
      • 5.5.2.9 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Application
      • 5.5.3.4 End User
      • 5.5.3.5 Technology
      • 5.5.3.6 Form
      • 5.5.3.7 Component
      • 5.5.3.8 Process
      • 5.5.3.9 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Application
      • 5.5.4.4 End User
      • 5.5.4.5 Technology
      • 5.5.4.6 Form
      • 5.5.4.7 Component
      • 5.5.4.8 Process
      • 5.5.4.9 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Application
      • 5.5.5.4 End User
      • 5.5.5.5 Technology
      • 5.5.5.6 Form
      • 5.5.5.7 Component
      • 5.5.5.8 Process
      • 5.5.5.9 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Application
      • 5.5.6.4 End User
      • 5.5.6.5 Technology
      • 5.5.6.6 Form
      • 5.5.6.7 Component
      • 5.5.6.8 Process
      • 5.5.6.9 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Application
      • 5.6.1.4 End User
      • 5.6.1.5 Technology
      • 5.6.1.6 Form
      • 5.6.1.7 Component
      • 5.6.1.8 Process
      • 5.6.1.9 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Application
      • 5.6.2.4 End User
      • 5.6.2.5 Technology
      • 5.6.2.6 Form
      • 5.6.2.7 Component
      • 5.6.2.8 Process
      • 5.6.2.9 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Application
      • 5.6.3.4 End User
      • 5.6.3.5 Technology
      • 5.6.3.6 Form
      • 5.6.3.7 Component
      • 5.6.3.8 Process
      • 5.6.3.9 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Application
      • 5.6.4.4 End User
      • 5.6.4.5 Technology
      • 5.6.4.6 Form
      • 5.6.4.7 Component
      • 5.6.4.8 Process
      • 5.6.4.9 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Application
      • 5.6.5.4 End User
      • 5.6.5.5 Technology
      • 5.6.5.6 Form
      • 5.6.5.7 Component
      • 5.6.5.8 Process
      • 5.6.5.9 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Ironwood Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Salix Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Almirall
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Ferring Pharmaceuticals
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Ardelyx
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Red Hill Biopharma
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Phathom Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Antibe Therapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Innovate Biopharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Progenity
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Synthetic Biologics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Genfit
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Galectin Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 9 Meters Biopharma
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Trulance
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Iterum Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Assembly Biosciences
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Adare Pharmaceuticals
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Theravance Biopharma
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Sterna Biologicals
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us